SLAMF7 and Miyoshi myopathy: SLAMF7 targets have been identified as a promising alternative antigen due to their absence in both epithelial tissues and hematopoietic stem cells Furthermore, over 95% of bone marrow MM cells express SLAMF7, and this expression persists throughout relapse and treatment with standard therapies.